2-amino-5-[2-[2-[(2R)-2-methylpyrrolidin-1-yl]ethyl]imidazo[1,2-a]pyridin-6-yl]pyridine-3-carbonitrile | 1307240-82-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-amino-5-[2-[2-[(2R)-2-methylpyrrolidin-1-yl]ethyl]imidazo[1,2-a]pyridin-6-yl]pyridine-3-carbonitrile
• CAS: 1307240-82-9
• 化学式: C₂₀H₂₂N₆
• 分子量: 346.435
• InChiKey: URVNGALJCOAHQS-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  83.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS D'IMIDAZOLE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SCHERING CORP

  公开号：WO2011060235A1

  公开（公告）日：2011-05-19

  The present invention relates to novel imidazole compounds, pharmaceutical compositions comprising the imidazole compounds and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below:

  本发明涉及新型咪唑化合物，包括该咪唑化合物的药物组成物，并使用这些化合物来治疗或预防过敏、过敏引起的气道反应、充血、心血管疾病、炎症性疾病、胃肠道疾病、神经系统疾病、代谢性疾病、肥胖症或与肥胖相关的疾病、糖尿病、糖尿病并发症、糖耐量受损或空腹血糖受损。本发明的一种示例化合物如下所示：
• IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF
  申请人：Rao Ashwin U.

  公开号：US20120225885A1

  公开（公告）日：2012-09-06

  The present invention relates to novel imidazole compounds, pharmaceutical compositions comprising the imidazole compounds and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: